Decrease of Tyrosine Kinase Inhibitor in Patients with CML

ASHReport has 142 videos Subscribe Here

Description: Mhairi Copland, BSc (Hons) MB ChB PhD FRCP FRCPath of the University of Glasgow, presents a press briefing of Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study at the 58th ASH Annual Meeting in San Diego, CA.
Shared By : ASHReport
Posted on : 12/07/16
Added : 1 year ago


Nothing found.

More From ASHReport

Nothing found.